Cancer Immunology Reserch

IL-10R inhibition induces neutrophil tumoricidal activity

by

Cancer Immunol Res. 2026 Jan 7. doi: 10.1158/2326-6066.CIR-25-0834. Online ahead of print. ABSTRACT While the role of neutrophils in modulating antitumor T cell responses has been extensively studied, their direct effects on tumor cells remains less well understood. In this study, we investigated whether neutrophils have the capacity to directly kill tumor cells independently of … Read more

The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B-cell Lymphoma

by

Cancer Immunol Res. 2025 Dec 29. doi: 10.1158/2326-6066.CIR-25-0583. Online ahead of print. ABSTRACT Relapsed and refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) presents a significant challenge in hematology-oncology, with approximately 30-40% of DLBCL patients experiencing relapse or resistance to treatment. This underscores the urgent need to better understand the molecular mechanisms governing therapeutic resistance. Signal Transducer … Read more

Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFN-γ-ΙRF1-SREBF2 Axis

by

Cancer Immunol Res. 2025 Dec 9. doi: 10.1158/2326-6066.CIR-25-0242. Online ahead of print. ABSTRACT Tumor cells employ metabolic mechanisms to limit antitumor immunity and promote resistance to immunotherapy. However, how immunotherapy modulates tumor metabolism remains unclear. Here, we demonstrated that anti-PD-1 treatment regulated cholesterol biosynthesis in cancer cells through the effector cytokine interferon IFN-γ. Mechanistically, IFN-γ-induced … Read more

A universal boosting strategy for adoptive T cell therapy using a paired vaccine/chimeric antigen receptor

by

Cancer Immunol Res. 2025 Dec 8. doi: 10.1158/2326-6066.CIR-25-0070. Online ahead of print. ABSTRACT Vaccines that encode tumour-associated antigens are potent boosting agents for adoptively transferred tumour-specific T cells. Employing vaccines to boost adoptively transferred tumour-reactive T cells relies on a priori knowledge of tumour epitopes, isolation of matched epitope-specific T cells, and personalized vaccines, all … Read more

T cell priming by high avidity neoantigens in lymph nodes augments adoptive immunotherapy

by

Cancer Immunol Res. 2025 Dec 5. doi: 10.1158/2326-6066.CIR-25-0514. Online ahead of print. ABSTRACT Adoptive transfer of T lymphocytes specific for tumor-associated neoantigens can elicit immunity against solid tumors in patients. However, how these antigens impact T cell function, effector differentiation, and persistence remains unclear. We examined how an identical CD8+ T cell product was shaped … Read more

The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy

by

Cancer Immunol Res. 2025 Dec 1:OF1-OF12. doi: 10.1158/2326-6066.CIR-25-0631. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of cancer. However, the durable response to this therapy remains low, and there is a risk of moderate-to-severe toxicities following treatment that requires close monitoring. Over the past decade, we have learned … Read more

Pyroptosis modulates multiple immune cell populations in targeted therapy-treated melanoma

by

Cancer Immunol Res. 2025 Nov 26. doi: 10.1158/2326-6066.CIR-25-0444. Online ahead of print. ABSTRACT Treatment of melanoma with BRAF inhibitors plus MEK inhibitors (BRAFi + MEKi) stimulates an intratumoral immune response, in part through pyroptosis mediated by the pore-forming protein gasdermin E (GSDME/Gsdme). How GSDME mediates effects on tumoral immunity is not well characterized. Using single-cell … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520